Answers are grounded in this paper and cite their sources.
The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future. Outstanding question is maintenance of the weight loss, possibly pharmacological treatment needs to be life-long.
No takes yet. Share an insight, caveat, or question.
Madsbad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: